RegenLab USA (Updated)
| General Information | |
| Business: | (Incorporated in Delaware)RegenLab is a science-driven regenerative medicine company originally founded in Switzerland and now structured under RegenLab USA, Inc., our U.S.-based holding entity. We operate through a fully integrated platform with three manufacturing sites and dedicated R&D and clinical teams based in New Jersey (USA), Paris (France), and Monthey (Switzerland). Across these sites, we maintain full control of the development and industrialization cycle, including GMP manufacturing, clinical and regulatory affairs, and global IP management. RegenLab is the holder of over 70 granted patents, covering proprietary blood-processing devices (Platelet Rich Plasma, or “PRP”), crosslinked scaffolds, combination products (PRP with Hyaluronic Acid (“HA”)), bone marrow–derived solutions, and bioengineered matrices designed for point-of-care preparation and safe, reproducible use across outpatient and surgical settings.We have numerous products across different stages of regulatory approval in both CE-MDR and FDA frameworks, including active PMA and 510(k) pathways.RegenLab has built a modular regenerative product platform that enables tailored solutions across multiple therapeutic areas, notably: -A stratified osteoarthritis platform designed to address all Kellgren-Lawrence (“KL”) grades (II to IV) with standardized offerings, including: (1) Arthrovisc, our CE-MDR product using HA-alone syringes for Grade II KL; (2) Regenkit, our CE-MDR and FDA cleared product utilizing PRP-only solutons for Grade II KL; (3) Cellular Matrix, our CE-MDR product, witha PMA in process, integrating PRP with linear HA for Grade III KL, and (4) RegenMatrix, our pipeline product, integrating PRP with crosslinked HA. -An expanding wound care platform, anchored by RegenWound, our gel-based autologous product currently reimbursed by CMS in the U.S. for chronic wound management and under commercialization through key partnerships, as well as our newly EU-MDR certified Cellular Membrane product (also referred to herein as CellularWound). -Emerging platforms targeting tissue repair and regenerative surgery, including bioresorbable electrospun implants, PRP-enhanced matrices, and next-generation gelation systems integrating calcium gluconate or tranexamic acid for hemostatic and anti-inflammatory applications. Through this vertically integrated model, RegenLab has achieved direct control over all critical functions — from core IP ownership, to R&D, device design, engineering & manufacturing, clinical validation, and regulatory execution — enabling us to deliver compliant, clinically validated, and scalable regenerative products in a rapidly evolving global market. RegenLab’s medical device products are commercialized through a mix of direct sales forces in key markets, including the United States, Switzerland, France, Germany and Spain and distribution partnerships.Our ProductsRegenLab is a global leader in autologous regenerative medicine, offering a fully integrated portfolio of standardized PRP, PRP-HA, and tissue engineering technologies across four major therapeutic domains: (1) Musculoskeletal (MSK) Regeneration; (2) Advanced Wound Care; (3) Medical Aesthetics/Dermatology and (4) Women’s Health/Urogynecology.RegenLab’s vertically integrated model extends beyond PRP to include crosslinked HA gels, nanofiber scaffolds, bioresorbable implants, and fibrin-based biomaterials, enabling a convergence of cell-based therapy and tissue engineering. Each of the four therapeutic platforms is built on a scalable, modular product suite, addressing disease severity and clinical workflow, which we believe opens up a combined global market opportunity exceeding $30 billion.Our products, pipeline and company strategy were originated and are supported by a management team with extensive experience and expertise in clinical research and development, business development and commercialization. Our founder, Chairman and CEO Antonino Turzi is a serial entrepreneur in the life sciences industry and an early leader in the biomaterials and tissue engineering industry. He is the author of more than 100 patents/patent applications. Dr. Giuseppe Calloni, the CEO of RegenLab USA, LLC has 25 years of executive management for public and private chemical and biotech organizations in Italy, France, Switzerland, China, and USA. He is the author of 25 scientific publications, 3 patents and 2 books.Note: Revenue is in U.S. dollars for the 12 months that ended on June 30, 2026.(Note: RegenLab USA filed its S-1/A on Oct. 27, 2026, and disclosed the terms for its small IPO: 2.5 million shares at a price range of $6.00 to $8.00 to raise $17.5 million, if priced at the $7.00 mid-point of its range. Background: RegenLab USA, Inc. filed its S-1 in September 2026 without disclosing the terms for its small IPO.) |
| Industry: | PHARMACEUTICAL PREPARATIONS |
| Employees: | 32 |
| Founded: | 2003 |
| Contact Information | |
| Address | 95 Greene Street Jersey City, New Jersey 07302 |
| Phone Number | 1 (800) 220–9082 |
| Web Address | https://regenlabusa.com/ |
| View Prospectus: | RegenLab USA (Updated) |
| Financial Information | |
| Market Cap | $157.24mil |
| Revenues | $54.27 mil (last 12 months) |
| Net Income | $ mil (last 12 months) |
| IPO Profile | |
| Symbol | RGNA |
| Exchange | NASDAQ |
| Shares (millions): | 2.5 |
| Price range | $6.00 - $8.00 |
| Est. $ Volume | $17.5 mil |
| Manager / Joint Managers | StoneX |
| CO-Managers | |
| Expected To Trade: | |
| Status: | TBA |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |